ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib is currently approved by the FDA for patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), particularly patients with tumors bearing the BCR-ABL T315I resistance mutation, suggesting that currently approved drugs may have an activity to ameliorate skeletal manifestations of NF134.